GLOW vs KLOW Peptide Stacks: What's Inside, Dosage Charts, Results & Risks

Key takeaways

• GLOW is a seller's name for one vial holding three research peptides, usually 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. KLOW adds 10 mg of KPV. Neither is a product that any pharmacy, company or regulator has defined.
• The human evidence for the parts: topical GHK-Cu has small cosmetic studies and no injectable data; BPC-157 has three tiny uncontrolled pilots (16, 12 and 2 people) from one clinic; TB-500 has none; KPV has none. No study of any blend exists.
• The dosing charts (10 to 20 units a day of a 70 or 80 mg vial in 2 to 3 mL, five days a week, for 4 to 12 weeks) are seller arithmetic, not studied doses. Per injection they deliver about 0.5 mg of BPC-157 and TB-500 each, far below what the pilots used, and about 2.5 mg of GHK-Cu, which no human has been studied receiving.
• As of October 2026 no US pharmacy may compound BPC-157, TB-500, KPV or injectable GHK-Cu. The July 2026 advisory votes changed nothing yet. Every GLOW or KLOW vial is a research chemical, and FDA warned five vendors in August 2026 that research labels do not protect sellers of drugs intended for people.
• The risks are the risks of injecting an unverified four-compound mix: contamination and endotoxin, wrong content, immune reactions, copper load, and blood-vessel and tumor signaling nobody has studied in combination. A 'results' post cannot separate any of that from lighting, filters and placebo.

What is in a GLOW vial, and what KLOW adds

GLOW is not a compound. It is a marketing name for a blend: three peptides that a seller has freeze-dried together in one vial so that the buyer reconstitutes and injects them as one solution. The name comes from the skin claims (copper peptide for 'glow') with two healing peptides added, and the typical vial, as listed by research-chemical sellers and summarized in a September 2026 magazine piece, holds 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500, a 70 mg total (Resident 2026). KLOW is the same blend plus 10 mg of KPV, for 80 mg. Vial sizes and ratios vary by seller; some sell a 50 mg GLOW, and some add a fifth compound. There is no standard, because there is no product, only a label.

Two things follow. By weight, GLOW and KLOW are mostly copper peptide; the healing peptides that carry the reputation are a small fraction of each injection. And the ratio is fixed by the seller, so no component can be adjusted without changing the others.

The evidence, one component at a time

GHK-Cu

GHK-Cu is a natural tripeptide bound to copper that stimulates collagen and matrix repair in cells and animals, and it has a cosmetic track record: small 12-week studies in 40 to 70 women reporting firmer, thicker skin and fewer fine lines, mostly as conference abstracts; one positive 1994 trial in diabetic foot ulcers (Mulder 1994); one negative trial in venous ulcers; one negative post-laser trial; and one 18-person eyebrow study in 2026. All of that is topical. There is no published human study of injected GHK-Cu for any purpose, a gap the 2026 independent review of the molecule calls one of the clearest between the biology and a usable product (Mateescu 2026). The full story, including the copper question, is in our GHK-Cu profile.

BPC-157

BPC-157 is a 15-amino-acid synthetic fragment of a protein found in gastric juice. Hundreds of rodent papers, largely from one group in Zagreb, show faster healing of tendon, ligament, muscle, gut and blood vessels; a 2025 narrative review found the preclinical work robust, the human data extremely limited, and every published study positive, which is a sign of publication bias rather than of a perfect drug (McGuire 2025). Three human pilots exist, all from one Florida clinic: a retrospective chart review of 17 knee-pain patients given intra-articular BPC-157, 16 reached by phone and 14 reporting relief, with no control group, no validated outcome measure and no reported dose (Lee 2021); an uncontrolled study of 12 women with interstitial cystitis given a single 10 mg bladder-wall injection; and a safety pilot in which two adults received 10 mg and then 20 mg intravenously with no change in blood tests (Lee 2025). The manufacturer's inflammatory bowel disease program in the early 2000s surfaced only as a conference abstract. Our BPC-157 profile grades the claims in detail.

TB-500

TB-500 is sold as thymosin beta-4, a 43-amino-acid protein every cell makes that promotes cell migration, blood-vessel growth and wound repair; the full protein has had early-phase human trials in venous ulcers, eye disease and heart injury, mostly sponsored by its developer (Goldstein 2012). What is in a TB-500 vial is usually not that protein: a Belgian doping-control laboratory that analyzed TB-500 in 2012 identified the active ingredient as Ac-LKKTETQ, a seven-amino-acid acetylated fragment of thymosin beta-4 (Esposito 2012). The fragment has no human studies. When FDA's advisory committee reviewed it in July 2026, the agency's reviewers said there are no studies of TB-500 itself and raised a possible cancer signal; the committee voted 8 to 6 to recommend it anyway (Hyman Phelps 2026). Our TB-500 profile covers the thymosin trials and the fragment problem.

KPV

KPV is lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), the hormone that darkens skin and, separately, calms inflammation. The fragment keeps the anti-inflammatory activity and loses the pigment effect, which is why immunologists have studied it since 1989, when it reduced chemically induced ear swelling in mice (Brzoska 2008). The best-known work is in bowel inflammation: nanomolar KPV blocked NF-kappa-B and MAP-kinase signaling in human intestinal cell lines, and KPV in drinking water reduced chemically induced colitis in mice through the PepT1 transporter (Dalmasso 2008); a German group found the same in two mouse colitis models (Kannengiesser 2008). There is no published human trial of KPV for any condition. On July 23, 2026, FDA's advisory committee voted 8 to 6, with one abstention, to recommend KPV for the compounding list for wound healing and inflammatory conditions, over FDA reviewers' objections about absent human data and uncertain product identity (Kelley Drye 2026); nothing has been compoundable since, because FDA has not issued a rule.

The components of GLOW and KLOW, graded by the human evidence for what sellers claim

Claim	Grade	What the evidence shows	Sources
GHK-Cu improves skin when applied topically	C	Small 12-week cosmetic studies in 40 to 70 women, mostly conference abstracts; one positive diabetic-ulcer trial, one negative venous-ulcer trial, one negative post-laser trial. Effects, where found, are modest.	Mateescu 2026; Mulder 1994
GHK-Cu improves skin, hair or healing when injected	D	No human study of injected GHK-Cu on its own exists. Clinicians interviewed by NPR in September 2026 advise against injecting it until there is one.	Mateescu 2026; NPR 2026
BPC-157 heals injuries or relieves pain in people	C	Three uncontrolled pilots from one clinic: 16 knee-pain patients surveyed by phone, 12 women with interstitial cystitis, and a 2-person IV safety study. No randomized trial. Rodent data are extensive, mostly from one group, and uniformly positive.	Lee 2021; Lee 2025; McGuire 2025
TB-500 speeds tendon, muscle or skin repair	D	TB-500 vials contain a 7-amino-acid fragment of thymosin beta-4, which has no human studies; the full protein has early-phase trials in ulcers and eyes. FDA reviewers in July 2026 noted no studies of TB-500 itself and a possible cancer signal.	Esposito 2012; Goldstein 2012; Hyman Phelps 2026
KPV reduces inflammation (gut, skin, joints)	D	Mouse colitis and ear-swelling models and human cell lines; no human trial of KPV for any condition. Recommended for the compounding list by an 8 to 6 committee vote in July 2026 with no rule issued.	Dalmasso 2008; Kannengiesser 2008; Brzoska 2008; Kelley Drye 2026
The components are synergistic when blended	D	No study of GLOW, KLOW or any combination of these peptides exists in humans or animals. The word synergy on a sales page is a hypothesis.	Resident 2026; Mayfield 2026
Injecting the blend is safe	D	No safety data on the blend. Analyses of research-vial peptides bought online found purity from 5 to 75 percent, arsenic above parenteral limits in several samples and lead in one, mislabeled content and endotoxin in every sample tested; none of it is specific to GLOW, all of it applies to the supply chain GLOW comes from.	Janvier 2018; Ashraf 2024; Moiz 2026

No one has studied the blend

The claim at the center of GLOW and KLOW marketing is synergy: that the components do more together than apart. It is not an unreasonable hypothesis, and it is untested. There is no animal study, let alone a human one, of these peptides in combination, and the 2026 orthopaedic primer that reviewed each of them concluded that indications, dosing, frequency and duration remain unknown for the components, never mind the mixture (Mayfield 2026).

A blend also raises questions a single peptide does not. Copper is the active part of GHK-Cu, and copper binds histidine and lysine residues on other peptides; BPC-157, the TB-500 fragment and KPV all contain lysine. Whether the copper stays on GHK when four peptides are dissolved together, redistributes or precipitates has not been measured for any blend; the 2026 pharmaceutics review notes that what counts as GHK-Cu depends on the formulation and is rarely characterized even in single-ingredient products (Mateescu 2026). The pharmacology is equally blank, and if one component causes a reaction, nothing in a four-compound injection tells you which.

The dosing charts sellers circulate, next to what was studied

What the charts say

The charts are internally consistent arithmetic, and a reconstitution calculator will reproduce them for any vial. The arithmetic is the only part that can be checked.

What was actually studied, per component

Set the two tables side by side and the chart falls apart in both directions. A daily GLOW injection delivers about half a milligram of BPC-157, twenty to forty times less than the single doses used in the only human pilots, so even if those pilots meant something, the chart does not reproduce them. And it delivers about 2.5 mg of GHK-Cu, roughly 0.4 mg of elemental copper, every day, which no human study has ever examined by any route. Over a five-day week that is about 2 mg of copper injected past the gut, the organ that normally decides how much copper gets in; see the copper arithmetic in the GHK-Cu profile.

The legal reality in October 2026

A blend is only as legal as its least legal component, and all four of GLOW's and KLOW's components fail the same test. Under section 503A, a licensed pharmacy may compound a bulk substance only if it has a USP monograph, is a component of an FDA-approved drug, or appears on FDA's permitted list (FDA 503A). None of these peptides passes.

The July 2026 votes are the detail most often misreported. An advisory committee recommended BPC-157, KPV and TB-500 for the permitted list, in each case over the objection of FDA's own reviewers, who cited missing human data, poorly characterized products and immunogenicity risk (Hyman Phelps 2026). A recommendation is not a rule: FDA must publish a proposed rule, take comments and finalize it, which the lawyers who follow the committee expect to take months at least, and it is not obliged to follow the vote (Kelley Drye 2026). The April removal from Category 2 was narrower still: the nominations were withdrawn and the safety flag lifted, which does not make the substances eligible for compounding, especially while the only available material is research-grade, which cannot lawfully go into a compounded drug (Frier Levitt 2026). Our legal tracker follows each of these.

So every GLOW or KLOW vial, including the ones dispensed by a clinic with an intake form and a 'physician-supervised' label, is a research chemical. In August 2026 FDA sent warning letters to five online peptide vendors making exactly this point: research-use disclaimers do not change the legal analysis when the website shows the product is intended for people, and the agency cited dosing guides, injection instructions and bundled bacteriostatic water as the evidence (ArentFox Schiff 2026). A GLOW dosing chart is that evidence.

What the research supply chain actually contains

Because no pharmacy is involved, the only published information about what is in research-vial peptides comes from laboratories that bought and tested them. A Belgian public-health laboratory profiled the ten most common falsified peptide drugs from illegal online pharmacies and found purity of 5 to 75 percent for cysteine-containing peptides, large variation in content per vial, and toxic metals: arsenic in several samples at up to ten times the limit for injectable drugs, and lead in one (Janvier 2018). A 2024 test-purchase study of semaglutide vials from online sellers found purity of 8 to 14 percent against a labeled 99 percent, content 29 to 39 percent above label, and endotoxin in every sample (Ashraf 2024). Neither tested GLOW; both tested the market GLOW is sold in, and a certificate of analysis posted by the seller is a document the seller controls.

Risks of injecting an unverified four-compound mix

• Contamination and endotoxin. Research vials are not made under sterile-drug rules, and endotoxin, the bacterial residue that causes fever, chills, low blood pressure and in severe cases shock, survives filtration. In 2026 it did not take a research vial to cause harm: FDA reported about 30 adverse events from compounded glutathione injections made with the wrong grade of powder, described in our glutathione profile, and a research vial has less oversight than those pharmacies had.
• Wrong content. Purity, identity and amount are unverified, and the published analyses of comparable products found all three off by large margins (Janvier 2018).
• Immune reactions. FDA's stated reason for flagging injectable GHK-Cu in 2023 was immunogenicity from aggregates and impurities; its reviewers raised the same concern for BPC-157, TB-500 and KPV in July 2026 (Hyman Phelps 2026).
• Copper. About 0.4 mg of elemental copper per daily injection, bypassing intestinal regulation, with no human data on where it goes; a 2026 cardiology review lists oxidative stress and liver injury as the theoretical consequence (Moiz 2026).
• Blood-vessel and tumor signaling. BPC-157 raises VEGF receptor signaling and TB-500 raises matrix metalloproteinases and endothelial migration, which is how they heal wounds in animals and also why reviewers worry about occult tumors; FDA reviewers raised a possible cancer signal for TB-500 (Moiz 2026). No human data exist in either direction, which is the point: nobody who injects GLOW has been followed.
• No attribution. With four unlabeled compounds in one syringe, a rash, a fever, a liver-enzyme rise or a mood change cannot be assigned to any of them, and there is no pharmacist or prescriber to report it to.
• Sport. BPC-157 and TB-500 are prohibited by WADA at all times; a GLOW vial is a positive test waiting to happen.

The 'results' genre

Search any of these names and the results tab fills with before-and-after photos, 30-day diaries and 'my GLOW results' videos. A photo cannot separate four peptides from lighting, filters, a new retinoid, weight change, hydration or the expectation of the person who paid for the vial, and the people posting are often the people selling. The one outcome GLOW could plausibly deliver, the modest skin-texture change seen in topical copper peptide studies, does not require a needle, and those studies are small enough that an independent 2026 review described the whole GHK-Cu clinical case as resting on studies of a dozen participants (Mateescu 2026). For the healing claims, the only human data are a phone survey and a two-person safety study (Lee 2021). Everything else is a testimonial, the content FDA's 2026 warning letters treated as marketing of an unapproved drug.

What the honest alternatives look like

If the goal is skin, topical copper peptide has small studies behind it and prescription retinoids and sunscreen have large ones; see the GHK-Cu profile. If the goal is a tendon, a joint or a gut problem, the components of GLOW have no human trial between them, and the BPC-157 and TB-500 profiles explain what the animal data do and do not promise while FDA decides whether pharmacies may ever make them. If the goal is inflammation, KPV is a mouse result with a committee vote attached. No version of GLOW or KLOW can be prescribed from a licensed pharmacy in October 2026, and this page will say so until that changes.

Bottom line

GLOW and KLOW are names on a research vial, not medications. Their components range from thinly studied (topical copper peptide) to unstudied in humans (injected copper peptide, the TB-500 fragment, KPV), with BPC-157 somewhere in between on the strength of three uncontrolled pilots from one clinic. No study of the blend exists. The dosing charts are seller arithmetic that delivers mostly copper and a fraction of the healing peptides it advertises. None of the four can be legally compounded for injection as of October 2026, so every vial comes from a supply chain whose published quality record is poor, and if something goes wrong there is no way to know which compound did it. The results posts prove that people inject it, not that it works.

Frequently asked questions

+−What is the GLOW peptide?

GLOW is a seller's name, not a drug. It refers to a single vial containing three research peptides freeze-dried together, most often 50 mg of GHK-Cu (copper peptide), 10 mg of BPC-157 and 10 mg of TB-500, sold for subcutaneous injection with skin, hair and healing claims. No company, pharmacy or regulator has defined the product, and no study has tested the mixture in people or animals.

+−What is the difference between GLOW and KLOW?

KLOW is GLOW plus KPV, a three-amino-acid fragment of the hormone alpha-MSH with anti-inflammatory effects in mice and cell cultures. Typical listings describe KLOW as 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV in one 80 mg vial. KPV has no human trials, so adding it adds a fourth unstudied compound rather than a fourth proven one.

+−What is the GLOW peptide dosage chart?

The charts sellers circulate usually say to reconstitute a 70 mg vial with 2 or 3 mL of bacteriostatic water and inject 10 to 20 units (0.1 to 0.2 mL) once a day, five days a week, for 4 to 12 weeks, which works out to about 2.3 to 7 mg of the blend per injection. None of those numbers come from a study; they are arithmetic applied to a vial size that a seller chose. We reproduce them so you can recognize them, not use them.

+−Where do people inject KLOW?

Sellers' instructions say subcutaneously, usually in the abdomen, and sometimes near the area the user hopes to improve. There is no pharmacokinetic reason to think injection site matters for a blend that enters the bloodstream, and no human data on where any of the four components go after injection. Since no legal KLOW product exists, there is no clinician-supervised version of this question.

+−Is the GLOW peptide legal? Can a doctor prescribe it?

Not as of October 2026. BPC-157, TB-500 and KPV were recommended for the compounding list by an FDA advisory committee on July 23, 2026, but FDA has not issued a rule, so no pharmacy may compound them; injectable GHK-Cu is awaiting its own committee review by February 2027 and cannot be compounded either. A prescription cannot make a non-compoundable substance compoundable, so every GLOW or KLOW vial is a research chemical regardless of who hands it to you.

+−What are the side effects of GLOW peptide injections?

Nobody has recorded them systematically, because the blend has never been studied. The known risks of research-vial injections apply: injection-site reactions and infections, fever and shock from endotoxin-contaminated vials, wrong doses from mislabeled content, and immune reactions to impurities. Component-specific concerns are copper load from GHK-Cu, and the blood-vessel and tumor-signaling questions FDA reviewers raised about TB-500 and that reviewers raise about BPC-157. If something goes wrong, there is no way to tell which of four compounds caused it.

+−Do GLOW before-and-after results prove it works?

No. Before-and-after photos cannot separate the peptides from lighting, filters, skincare, weight change, hydration and the wish to see a difference, and the people posting them are often selling. The only outcome GLOW could claim with a straight face, topical copper peptide's modest effect on skin texture, does not require a needle. Nothing about the injected blend has been measured.

+−Can I combine NAD+ with GLOW peptides?

There is no study of either in combination with the other, and NAD+ injections have their own thin evidence base. Combining an unstudied four-compound blend with a fifth compound makes any side effect impossible to attribute and does nothing to improve the evidence for any of them.

Sources

1. NewsResident magazine. The GLOW peptide blend: why everyone is searching for it, and what the science says (typical vial: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500; sold as research material). September 25, 2026. (2026)
2. NewsStone W. The copper peptide trend has gone from creams to injections, ahead of the science. NPR, September 7, 2026 (republished by WUNC). (2026)
3. ReviewMateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics 2026;18:1077. (2026)
4. StudyMulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen 1994;2:259-69. (1994)
5. ReviewMcGuire FP et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025;18:611-9. (2025)
6. StudyLee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021;27:8-13. (2021)
7. StudyLee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025;31:20-4. (2025)
8. ReviewGoldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012;12:37-51. (2012)
9. StudyEsposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012;4:733-8. (2012)
10. StudyDalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-78. (2008)
11. StudyKannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:324-31. (2008)
12. ReviewBrzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008;29:581-602. (2008)
13. ReviewMayfield CK et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med 2026;54:223-9. (2026)
14. ReviewMoiz A, O'Keefe EL, O'Keefe JH. Dangers of injectable peptides and other unregulated 'biohacking' drugs. Mo Med 2026;123:337-43. (2026)
15. StudyJanvier S et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta 2018;188:795-807. (2018)
16. StudyAshraf AR et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res 2024;26:e65440. (2024)
17. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c; FDA reviewers opposed all four; no studies of TB-500 itself; possible cancer signal). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
18. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know (proposed uses: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing). July 30, 2026. (2026)
19. NewsFrier Levitt. FDA to remove 12 popular peptides from the Category 2 'do not compound' list (BPC-157, KPV, TB-500 and injectable GHK-Cu among them; removal does not make them eligible for compounding; research-grade API cannot lawfully be used). April 16, 2026. (2026)
20. NewsArentFox Schiff. RUO-ined: five peptide vendors learn that research use only is not a legal strategy (FDA warning letters of August 24, 2026). September 18, 2026. (2026)
21. RegulatoryFDA. Bulk drug substances used in compounding under section 503A of the FD&C Act (the 503A bulks list and interim categories).